BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 12605277)

  • 1. FDG PET imaging guided re-evaluation of histopathologic response in a patient with high-grade sarcoma.
    Vernon CB; Eary JF; Rubin BP; Conrad EU; Schuetze S
    Skeletal Radiol; 2003 Mar; 32(3):139-42. PubMed ID: 12605277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy.
    Schuetze SM; Rubin BP; Vernon C; Hawkins DS; Bruckner JD; Conrad EU; Eary JF
    Cancer; 2005 Jan; 103(2):339-48. PubMed ID: 15578712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical value of [18-F]] fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas.
    Schwarzbach MH; Dimitrakopoulou-Strauss A; Willeke F; Hinz U; Strauss LG; Zhang YM; Mechtersheimer G; Attigah N; Lehnert T; Herfarth C
    Ann Surg; 2000 Mar; 231(3):380-6. PubMed ID: 10714631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas.
    Benz MR; Czernin J; Allen-Auerbach MS; Tap WD; Dry SM; Elashoff D; Chow K; Evilevitch V; Eckardt JJ; Phelps ME; Weber WA; Eilber FC
    Clin Cancer Res; 2009 Apr; 15(8):2856-63. PubMed ID: 19351756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soft Tissue Sarcoma Response to Two Cycles of Neoadjuvant Chemotherapy: A Multireader Analysis of MRI Findings and Agreement with RECIST Criteria and Change in SUVmax.
    Favinger JL; Hippe DS; Davidson DJ; Elojeimy S; Roth ES; Lindberg AW; Ha AS
    Acad Radiol; 2018 Apr; 25(4):470-475. PubMed ID: 29273189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. F-18 FDG PET and PET/CT evaluation of response to chemotherapy in bone and soft tissue sarcomas.
    Iagaru A; Masamed R; Chawla SP; Menendez LR; Fedenko A; Conti PS
    Clin Nucl Med; 2008 Jan; 33(1):8-13. PubMed ID: 18097248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas.
    Evilevitch V; Weber WA; Tap WD; Allen-Auerbach M; Chow K; Nelson SD; Eilber FR; Eckardt JJ; Elashoff RM; Phelps ME; Czernin J; Eilber FC
    Clin Cancer Res; 2008 Feb; 14(3):715-20. PubMed ID: 18245531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sarcoma mid-therapy [F-18]fluorodeoxyglucose positron emission tomography (FDG PET) and patient outcome.
    Eary JF; Conrad EU; O'Sullivan J; Hawkins DS; Schuetze SM; O'Sullivan F
    J Bone Joint Surg Am; 2014 Jan; 96(2):152-8. PubMed ID: 24430415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis.
    Bastiaannet E; Groen H; Jager PL; Cobben DC; van der Graaf WT; Vaalburg W; Hoekstra HJ
    Cancer Treat Rev; 2004 Feb; 30(1):83-101. PubMed ID: 14766127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlating metabolic activity on 18F-FDG PET/CT with histopathologic characteristics of osseous and soft-tissue sarcomas: a retrospective review of 136 patients.
    Rakheja R; Makis W; Skamene S; Nahal A; Brimo F; Azoulay L; Assayag J; Turcotte R; Hickeson M
    AJR Am J Roentgenol; 2012 Jun; 198(6):1409-16. PubMed ID: 22623556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of positron emission tomography/computed tomography (PET/CT) imaging in the evaluation of sarcomas: A systematic review.
    Lim HJ; Johnny Ong CA; Tan JW; Ching Teo MC
    Crit Rev Oncol Hematol; 2019 Nov; 143():1-13. PubMed ID: 31449981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative [F-18]fluorodeoxyglucose positron emission tomography in pretreatment and grading of sarcoma.
    Eary JF; Conrad EU; Bruckner JD; Folpe A; Hunt KJ; Mankoff DA; Howlett AT
    Clin Cancer Res; 1998 May; 4(5):1215-20. PubMed ID: 9607579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Value of FDG PET/CT in Patient Management and Outcome of Skeletal and Soft Tissue Sarcomas.
    Sheikhbahaei S; Marcus C; Hafezi-Nejad N; Taghipour M; Subramaniam RM
    PET Clin; 2015 Jul; 10(3):375-93. PubMed ID: 26099673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma.
    Nieweg OE; Pruim J; van Ginkel RJ; Hoekstra HJ; Paans AM; Molenaar WM; Koops HS; Vaalburg W
    J Nucl Med; 1996 Feb; 37(2):257-61. PubMed ID: 8667056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression.
    Rajendran JG; Wilson DC; Conrad EU; Peterson LM; Bruckner JD; Rasey JS; Chin LK; Hofstrand PD; Grierson JR; Eary JF; Krohn KA
    Eur J Nucl Med Mol Imaging; 2003 May; 30(5):695-704. PubMed ID: 12632200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic role of simultaneous PET/MRI-MRS in soft tissue sarcoma metabolism imaging.
    Zhang X; Chen YL; Lim R; Huang C; Chebib IA; El Fakhri G
    Magn Reson Imaging; 2016 Apr; 34(3):276-9. PubMed ID: 26523656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Value of FDG positron emission tomography in conjunction with MR imaging for evaluating therapy response in patients with musculoskeletal sarcomas.
    Bredella MA; Caputo GR; Steinbach LS
    AJR Am J Roentgenol; 2002 Nov; 179(5):1145-50. PubMed ID: 12388489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis.
    Eary JF; O'Sullivan F; Powitan Y; Chandhury KR; Vernon C; Bruckner JD; Conrad EU
    Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1149-54. PubMed ID: 12192559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between glycolytic phenotype and tumor grade in soft-tissue sarcomas by 18F-FDG PET.
    Benz MR; Dry SM; Eilber FC; Allen-Auerbach MS; Tap WD; Elashoff D; Phelps ME; Czernin J
    J Nucl Med; 2010 Aug; 51(8):1174-81. PubMed ID: 20660389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of repeated F-18 fluorodeoxyglucose imaging in management of patients with bone and soft tissue sarcoma.
    el-Zeftawy H; Heiba SI; Jana S; Rosen G; Salem S; Santiago JF; Abdel-Dayem HM
    Cancer Biother Radiopharm; 2001 Feb; 16(1):37-46. PubMed ID: 11279796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.